Table 2 Distribution of clinical parameters according to ERα/Src expression
Variable | ERα/SRC ≤10, no. (%) | ERα/SRC >10, no. (%) | P* | |
|---|---|---|---|---|
Age groups | ≤50 years | 76 (29.7) | 35 (20.1) | 0.026 |
>50 years | 180 (70.3) | 139 (79.9) | ||
T. size | ≤2 cm | 152 (59.4) | 97 (55.7) | 0.455 |
>2 cm | 104 (40.6) | 77 (44.3) | ||
LN invasion | No | 108 (42.2) | 74 (42.5) | 0.944 |
Yes | 148 (57.8) | 100 (57.5) | ||
SBR grade | Gr 1 | 44 (17.2) | 37 (21.3) | 0.394 |
Gr 2 | 129 (50.4) | 77 (44.3) | ||
Gr 3 | 83 (32.4) | 60 (34.5) | ||
ERα status | Negative | 34 (13.3) | 21 (12.1) | 0.712 |
Positive | 222 (86.7) | 153 (87.9) | ||
PR status | Negative | 61 (23.8) | 47 (27.0) | 0.455 |
Positive | 195 (76.2) | 127 (73.0) | ||
HER2 status | Negative | 238 (83.7) | 157 (91.3) | 0.345 |
Positive | 16 (6.3) | 15 (8.7) | ||
Breast Cancer subtype | Luminal A | 146 (57.0) | 95 (54.6) | 0.876 |
Luminal B | 76 (29.7) | 58 (33.3) | ||
HER2 rich | 7 (2.7) | 4 (2.3) | ||
TNBC | 27 (10.5) | 17 (9.8) | ||
Type of adjuvant hormonal | Tamoxifen | 93 (42.3) | 78 (52.3) | 0.057 |
AI | 127 (57.7) | 71 (47.7) | ||